Sell / TrimIPNP
Pharmaceuticals & Biotechnology
Ipsen SA
Recommends selling the holding, citing Somatuline generic competition, product concentration and acquisition risk, with a €135 target price.
Giorgio Donzelli
24 Sept 2026 · 8 pages
Research
Research archive
Every recommendation starts as a paper written by a member. Browse by year, type or topic.
Year
Type
18 papers
2026–27
2 papersSell / TrimNOVO
Healthcare
Novo Nordisk
Recommends selling Novo Nordisk at a US$94.50 target price against a US$114.30 share price, examining competition from Eli Lilly, lower US prices and semaglutide patent expiry.
Koichi Sakamoto, Yohan Jegou
24 Sept 2026 · 13 pages
2025–26
16 papersBuy8001.T
Consumer & Trading
Itochu Corporation
Japan's diversified trading conglomerate, spanning textiles, metals, food, energy and ICT. Recommends a £2,200 position (about 4% of the portfolio) with a ¥2,457 target price.
Alex Arbuthnott
4 Jun 2026 · 14 pages
BuyUTIL.L
Utilities
SPDR MSCI Europe Utilities UCITS ETF
A defensive, 95% European utilities ETF (€260.25, €801m AUM) suited to a 5-year horizon. Recommends a £2,000 allocation, about 3% of the portfolio.
Alex Arbuthnott
7 May 2026 · 12 pages
Sell / TrimIQV
Healthcare
IQVIA Holdings
A global leader in healthcare data and contract research ($170.93 per share, $29B market cap). Sets out the case to sell or trim the holding.
James Saunders
12 Mar 2026 · 9 pages
Sell / TrimPG
Consumer Staples
Procter & Gamble
A $84B-revenue consumer staples giant selling in 180+ countries. Argues the shares are overvalued relative to peers and recommends selling.
Alex Arbuthnott
12 Mar 2026 · 11 pages
Portfolio review
Portfolio
ECHCIC Portfolio Performance Summary (YTD)
Reviews the portfolio from 3 Jan to 7 Mar 2026 against the S&P 500 (−0.96%) and FTSE 100 (+2.99%). A 20.3% defence weighting drove most of the +0.66pp alpha over the S&P 500.
Taro Sakamoto
7 Mar 2026 · 5 pages
Macro
Geopolitics & Energy
The Impact of the Iran War on the ECHCIC Portfolio
Assesses market risk after 28 February: Brent rose from about $72 to $87, with the Strait of Hormuz (one fifth of oil transport) the key tail risk for the portfolio.
Taro Sakamoto
7 Mar 2026 · 2 pages
BuyTTE
Energy
TotalEnergies SE
An integrated 'multi-energy' major combining oil, gas, LNG, refining and power. Buy case built on upstream cash flow and LNG growth, with a €69 target price.
Taro Sakamoto, Kit Leighton
5 Mar 2026 · 13 pages
Macro
Interest Rates
How Global Interest Rates Shape Our Investments
Maps the shift to cautious, divergent easing: the Fed cut from 5.25–5.50% to 3.75%, the ECB to 2.00% and the Bank of England to 3.75%. Draws out what it means for the portfolio.
Eddy Thom, Mark Palamarchuk
27 Feb 2026 · 7 pages
Buy0700.HK
Technology
Tencent Holdings
WeChat-led Chinese tech conglomerate trading at HK$551 against a HK$769 target. Recommends a £1,500 buy (3% of the portfolio) on valuation re-rating potential.
David Sotkilava
12 Feb 2026 · 8 pages
BuyCBRE
Real Estate
CBRE Group
The world's largest commercial real estate services firm. Recommends buying 10 shares with a $180–190 target price by January 2027.
Matteo Donzelli, Max Bracken-Smith
12 Feb 2026 · 11 pages
BuyVST
Utilities
Vistra Corp.
A 41,000 MW US integrated power and retail electricity company set to benefit from AI data-centre demand. $159.60 share price against a $237.53 average analyst target.
ECHCIC Research Team
12 Feb 2026 · 10 pages
BuyHOOD
Financials & Fintech
Robinhood Markets
Commission-free retail brokerage with crypto and prediction-market upside. Recommends a £1,500 buy against a $150 target price.
Eddy Thom, Mark Palamarchuk
15 Jan 2026 · 11 pages
Buy
Energy & Conglomerates
Reliance Industries
India's largest listed conglomerate across energy, retail and telecoms (Jio). Buy 85 shares (about $1,398) at $16.45 with a $20 target, lifting Asia and energy exposure to 15%.
Rishi Khajuria, Mahmoud Bah Bah
15 Jan 2026 · 10 pages
Strategy
Fixed Income
Fixed Income Investment Opportunities
Proposes placing 20–30% of the portfolio in 1–3 year A/BBB-rated bonds, using coupons to fund further investments and adding a new asset class.
Matteo Donzelli
Jan 2026 · 10 pages
BuyVKTX
Healthcare & Biotech
Viking Therapeutics
A clinical-stage obesity and metabolic-disease biotech built on its VK2735 pipeline. High-risk, high-reward buy with a $106 target price.
Eddy Thom, Mark Palamarchuk
20 Nov 2025 · 10 pages
Sell / TrimGOOGL
Technology
Alphabet
Alphabet made up 20% of the portfolio. Recommends trimming 17 of 37 shares to cut overexposure to tech and free up over $4,200 for diversification.
Taro Sakamoto, Aaran Nihalani
3 Oct 2025 · 9 pages